US Patent

US10206813 — Implants with controlled drug delivery features and methods of using same

Formulation · Assigned to Dose Medical Corp · Expires 2030-10-17 · 4y remaining

Vulnerability score 56/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects drug delivery devices and methods for treating ocular disorders, including controlled release of one or more drugs.

USPTO Abstract

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Drugs covered by this patent

Patent Metadata

Patent number
US10206813
Jurisdiction
US
Classification
Formulation
Expires
2030-10-17
Drug substance claim
No
Drug product claim
Yes
Assignee
Dose Medical Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.